Millennium Management
ADAP

Millennium Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Millennium Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200,000
Closed -$1.15M – 3937
2018
Q4 		$1.15M Sell
200,000
-445,400
-69% -$3.29M ﹤0.01% 2507
2018
Q3 		$8.75M Buy
645,400
+550,000
+577% +$5.77M 0.01% 1409
2018
Q2 		$1.13M Buy
+95,400
New +$1.19M ﹤0.01% 2763

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's ADAP Position: Q2 2025 in Review

Millennium Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 94,283 shares — an estimated $18.6K sold.

Millennium Management first reported a position in ADAP in Q2 2015 and held it in 40 quarters. The position peaked at $29.5M in Q3 2018. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Millennium Management reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 94,283 Adaptimmune Therapeutics shares in Q2 2025, an estimated $18.6K.
  • Millennium Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 40 quarters.
  • Millennium Management's Adaptimmune Therapeutics position peaked at $29.5M in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.